These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 38266063

  • 1. Atogepant: Mechanism of action, clinical and translational science.
    Boinpally R, Shebley M, Trugman JM.
    Clin Transl Sci; 2024 Jan; 17(1):e13707. PubMed ID: 38266063
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
    Porreca F, Navratilova E, Hirman J, van den Brink AM, Lipton RB, Dodick DW.
    Cephalalgia; 2024 Mar; 44(3):3331024241238153. PubMed ID: 38477313
    [Abstract] [Full Text] [Related]

  • 3. Atogepant: an emerging treatment for migraine.
    Rustichelli C, Avallone R, Ferrari A.
    Expert Opin Pharmacother; 2022 Apr; 23(6):653-662. PubMed ID: 35319319
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Update of Gepants in the Treatment of Chronic Migraine.
    Cho S, Kim BK.
    Curr Pain Headache Rep; 2023 Oct; 27(10):561-569. PubMed ID: 37656319
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Atogepant: First Approval.
    Deeks ED.
    Drugs; 2022 Jan; 82(1):65-70. PubMed ID: 34813050
    [Abstract] [Full Text] [Related]

  • 11. Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety.
    Singh A, Balasundaram MK.
    Clin Drug Investig; 2022 Apr; 42(4):301-308. PubMed ID: 35230651
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model.
    Thaliffdeen R, Yu A, Rascati K.
    Clin Drug Investig; 2024 Mar; 44(3):209-217. PubMed ID: 38381352
    [Abstract] [Full Text] [Related]

  • 14. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
    Dos Santos JBR, da Silva MRR.
    Eur J Pharmacol; 2022 May 05; 922():174902. PubMed ID: 35358493
    [Abstract] [Full Text] [Related]

  • 15. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
    Caronna E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P.
    Handb Clin Neurol; 2024 May 05; 199():107-124. PubMed ID: 38307640
    [Abstract] [Full Text] [Related]

  • 16. Pharmacologic characterization of atogepant: A potent and selective calcitonin gene-related peptide receptor antagonist.
    Moore E, Bell IM, Fraley ME, Burgey CS, White RB, Li CC, Regan CP, Danziger A, McGaraughty SP, Naseri Kouzehgarani G, Salvatore C, Banerjee P.
    Cephalalgia; 2024 Jan 05; 44(1):3331024231226186. PubMed ID: 38215228
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The preclinical discovery and development of atogepant for migraine prophylaxis.
    Baraldi C, Beier D, Martelletti P, Pellesi L.
    Expert Opin Drug Discov; 2024 Jul 05; 19(7):783-788. PubMed ID: 38856039
    [Abstract] [Full Text] [Related]

  • 19. Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD.
    Strassman AM, Melo-Carrillo A, Houle TT, Adams A, Brin MF, Burstein R.
    Cephalalgia; 2022 Aug 05; 42(9):933-943. PubMed ID: 35332801
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.